Medicaid Managed Care GLP-1 Coverage by Plan: 2026 Data

By The RX Index Editorial Team · Last verified: August 1, 2026 · Data snapshot: July 31, 2026 · Dataset version: 1.1

Sources: state Medicaid agencies, managed-care contracts and manuals, preferred drug lists, prior-authorization documents, CMS, FDA, KFF, and CMS State Drug Utilization Data

Educational reference. Not medical, legal, or individualized coverage advice.

Medicaid managed care GLP-1 coverage by plan is usually not decided from scratch by the plan. In 10 of the 11 state Medicaid programs in this census, the first authoritative document is a state preferred drug list, a common formulary, a statewide pharmacy administrator's list, or the state fee-for-service pharmacy policy. The plan may still receive the request, process the authorization, apply permitted operational rules, and handle an appeal. But in those states, the plan does not get a blank sheet of paper.

Three dates define this snapshot. Massachusetts removed adult-obesity coverage effective July 3, 2026. Utah's fee-for-service pilot carried a published authorization window ending June 30, 2026 and did not establish a managed-care obesity pathway for its four ACOs. Rhode Island still belongs in the July 31 census, although its enacted fiscal-year 2027 budget authorizes the state to remove GLP-1 coverage except when prescribed for type 2 diabetes. Indiana announced a forthcoming expansion on July 30, but the state said eligibility rules and timing would follow after the agreement is finalized. An announcement is not an operative coverage date.

Medicaid managed care GLP-1 coverage statistics: the national snapshot

Source: The RX Index Research, Medicaid GLP-1 Coverage Control & Plan Lookup Dataset, version 1.1, data snapshot July 31, 2026. The denominator is a count of named managed-care entities, not enrollment.

How the 11-state census reconciles to the January baseline

KFF's January 2026 analysis identified 13 state Medicaid programs covering GLP-1 drugs for obesity under fee-for-service: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin.

Source: KFF, January 2026 baseline; MassHealth Pharmacy Facts 278; Utah Medicaid GLP-1 prior-authorization form; Utah 2025 statewide provider-training pharmacy slides; Indiana's July 30 announcement.

Does Medicaid GLP-1 coverage actually vary by managed care plan?

Usually not at the base-formulary level. In 10 of the 11 states with an active adult-obesity pathway in this census, a state or common rule fixes the list, creates a minimum floor, or takes outpatient pharmacy away from the managed-care plan entirely. Rhode Island is the exception: each contractor may maintain its own drug formulary and prior-authorization rules.

The useful distinction is between authority and process.

So "call your plan" can be good process advice and still be incomplete authority advice. The first question is not merely which plan are you in? It is who wrote the rule that plan must follow?

What switching plans can and cannot change

In a carve-out, statewide-PBM, or fully common-formulary state, switching managed-care plans cannot create a different base drug list. In a state-floor model, switching plans cannot take away the state's required minimum, but it may change the route, documentation workflow, permitted utilization management, turnaround, or appeal handling. In Rhode Island, a plan change can change the base formulary itself.

That is why the page classifies the controlling architecture rather than pretending every "covered" row predicts an individual claim.

What this data shows — and what it does not

It shows which document to read first. Each row identifies whether the material base answer comes from a state carve-out, a statewide pharmacy administrator, a binding common list, a state floor, or the plan's own formulary.

It does not show that any individual person will be approved. A paid claim can still turn on the member's eligibility category, age, diagnosis, FDA-labeled indication, product, formulation, strength, quantity limit, step requirement, chart documentation, prior authorization, and the rule in effect on the date of service.

Three limits matter most:

This is educational reference material. It is not medical advice, legal advice, a coverage determination, or a guarantee of payment. Current coverage should be confirmed with the applicable state Medicaid program or health plan, and treatment decisions belong with a qualified clinician.

How we built the Medicaid managed care GLP-1 coverage dataset

We started with KFF's January 2026 fee-for-service survey, then rebuilt the question at the managed-care level. That distinction matters because the latest CMS beneficiary profile reports that 75.1% of Medicaid beneficiaries were enrolled in comprehensive managed care in 2022, the most recent year used in that profile. A fee-for-service state list is a national baseline; it is not a managed-care answer by itself.

Reproducibility of the headline count

The row-level count is:

Models 1 through 4 total 59. The full census totals 62. The published share is therefore 59 ÷ 62 = 95.2%, rounded to one decimal place.

Every total in this article is calculated from the plan rows below. None of the headline totals were typed independently of the row-level census.

Source: CMS, Medicaid and CHIP Beneficiary Profile; The RX Index Research calculation from the lookup rows below.

Does the state or the managed care plan control GLP-1 coverage?

There are five recurring architectures. The architecture tells you which document is authoritative before you get lost in plan names.

Source: The RX Index Research classification of the official state documents linked in the lookup and methodology, verified July 31, 2026.

Why Model 4 is still counted as state/common-controlled

Model 4 does not mean every request is identical across plans. It means the plan cannot write the base formulary answer without a state boundary.

That is materially different from Rhode Island, where the plan's proprietary formulary is itself the starting answer.

The distinction almost everyone misses: a drug list is not a set of prior-authorization criteria

A state can bind every plan to one list and still leave room in how a request is administered. For adult-obesity GLP-1 drugs, that distinction matters because the active pathways in this census commonly require prior authorization.

Four states show four versions of the rule.

North Carolina binds the list and the criteria. State law requires prepaid health plans to use the Department's preferred drug list, and NC Medicaid's managed-care pharmacy guidance says plans use the same prior-authorization criteria. The state owns both the list and the gate.

Delaware binds the floor, not the individual request. Delaware's PDL states that the clinical criteria printed in the document apply to fee-for-service. Managed-care requests are processed through the MCO under the MCO's criteria. The managed-care contract still requires the contractor's formulary to follow the state PDL at minimum. The state sets the floor; the plan administers the member-level request.

Minnesota binds the minimum list. Medical Assistance managed-care members receive the drugs required by the Uniform PDL plus any additional drugs their plan covers. The plan cannot subtract the state minimum.

Virginia binds the closed-class list. The current Virginia pharmacy manual says closed classes must be covered by fee-for-service and MCOs exactly as posted. The current PDL classifies Weight Management Agents as closed and lists Saxenda, Wegovy, and Zepbound with state service-authorization forms. Virginia's general member page still links to each plan's broader formulary because many drug classes remain plan-specific; that general fact does not override the closed-class rule for weight-management agents.

Practical consequence: the list tells you whether the drug sits inside the allowed pathway. The authorization criteria and documentation tell you whether a particular request can pass through it.

Sources: North Carolina managed-care pharmacy fact sheet; N.C.G.S. § 108D-65; Delaware Medicaid PDL, effective July 6, 2026; Minnesota Uniform PDL; Virginia Pharmacy Manual, Chapter IV; Virginia Medicaid PDL/Common Core Formulary.

Medicaid managed care GLP-1 coverage by plan: the full lookup

Below is every named managed-care entity in the July 31 census and the authority that materially controls the base pharmacy answer. Start with the controlling authority, then check indication, product, formulation, criteria, and effective date. The plan name alone is not an answer.

The Delaware PDL effective July 6, 2026 lists Wegovy and Zepbound in the obesity-agent class and requires prior authorization for anti-obesity agents. Delaware is not a pharmacy carve-out. The MCO provides the pharmacy benefit, while its formulary must follow the state PDL at minimum. Source: Delaware Medicaid Preferred Drug List, effective July 6, 2026; Delaware Medicaid managed-care information; Delaware MCO Master Service Agreement.

The current KanCare contracts run from January 1, 2025 through December 31, 2027. Kansas maintains the Medicaid PDL; its July 2026 list includes a weight-loss-agent class with Wegovy, Zepbound, and Saxenda entries. The plan remains the operational route for authorization. Source: Kansas Medicaid PDL; Kansas General Clinical Prior Authorization; KanCare managed-care contracts and plans.

Michigan's obesity-only pathway became narrower for dates of service on or after January 1, 2026. MDHHS Numbered Letter L 25-73 says GLP-1 requests solely for obesity require additional clinical conditions, including classification as morbidly obese and documented failure of other clinically appropriate weight-loss interventions, including preferred anti-obesity agents. Coverage for other existing indications was not changed by that letter. Source: Michigan Medicaid Health Plans; Michigan Common Formulary information, effective May 1, 2026; MDHHS Numbered Letter L 25-73.

Minnesota has required Medical Assistance MCOs to use the DHS Uniform PDL since July 1, 2019. It is a floor, not a ceiling: a member receives the state's required preferred drugs plus any additional drugs on the plan's own covered-drug list. The Uniform PDL does not apply to members with both Medicare and Medicaid. Source: Minnesota managed-care contracts; Minnesota Uniform Preferred Drug List; Uniform PDL effective January 1, 2026.

Since July 1, 2024, Mississippi's single pharmacy benefit administrator has processed pharmacy claims for Medicaid members, including MississippiCAN and CHIP, and assumed pharmacy prior-authorization responsibilities. The Universal PDL applies across the coordinated-care organizations. Source: Mississippi managed care; Mississippi single pharmacy benefit administrator implementation; Mississippi pharmacy program and Universal PDL.

Missouri carved outpatient pharmacy out of managed care effective October 1, 2009. Pharmacy claims for managed-care members are processed through the MO HealthNet fee-for-service pharmacy program. Home State Health's specialty product is not counted as a separate contractor. This version does not print an exact current preferred anti-obesity product for Missouri. The control model is verified; the product-level row was not independently reproduced from the operative state workbook, so it is not inferred. Source: MO HealthNet managed-care pharmacy carve-out notice; MO HealthNet pharmacy program; Missouri managed-care health plans.

North Carolina's state guidance says managed-care plans use the same PDL and the same prior-authorization criteria. The state ended GLP-1 coverage for weight management in October 2025 and reinstated it effective December 12, 2025 for NC Medicaid Direct and managed care. Both changes reached the plans through state policy. Source: NC Medicaid health plans; NC managed-care pharmacy fact sheet; NC Medicaid reinstatement notice; N.C.G.S. § 108D-65.

Rhode Island's current Medicaid managed-care pharmacy protocol lets each contractor establish its own drug formulary and prior-authorization requirements. This is the only state in the July 31 census where the plan's proprietary formulary determines the base answer. Date-sensitive: Rhode Island's enacted fiscal-year 2027 budget authorizes EOHHS to remove Medicaid coverage for GLP-1 medications except when prescribed to treat type 2 diabetes. Implementation materials identify October 1, 2026 as the scheduled change date. The current census includes Rhode Island on July 31 and marks the scheduled change for the next version. Source: Rhode Island Medicaid Managed Care Pharmacy Benefit Plan Protocols, effective January 1, 2026; Rhode Island 2025–2028 Medicaid and CHIP Quality Strategy; Rhode Island FY2027 budget as enacted; enacted Article 8 language.

All three TennCare MCOs use the statewide TennCare pharmacy list and clinical criteria administered through the state's pharmacy program. The PDL effective July 15, 2026 lists Wegovy and Zepbound as preferred GLP-1 weight-management agents, each with prior authorization and quantity limits. TennCare Select is administered under BlueCare and is not counted as a fourth MCO. Source: TennCare managed-care organizations; TennCare PDL effective July 15, 2026; TennCare clinical criteria.

Virginia's general member page links to each MCO's broader formulary, but that does not make every class plan-specific. The current pharmacy manual says closed classes must be covered by fee-for-service and MCOs exactly as posted. Weight Management Agents are a closed class in the state PDL/Common Core Formulary, with Saxenda, Wegovy, and Zepbound listed and state service-authorization forms linked. Source: Virginia Cardinal Care plans; Virginia Pharmacy Manual, Chapter IV, revised March 4, 2026; Virginia Medicaid PDL/Common Core Formulary; Virginia July 1, 2026 PDL update bulletin.

Wisconsin's BadgerCare Plus HMO guide states that pharmacy services, including prescription drugs and diabetic supplies, are not provided by the HMO and instead run through fee-for-service coverage. That makes all 13 HMO names irrelevant to the base outpatient-drug list. Source: Wisconsin BadgerCare Plus member information; Wisconsin BadgerCare Plus HMO Guide, January 2026; ForwardHealth PDL effective July 1, 2026.

Source for all plan tables: The RX Index Research, Medicaid GLP-1 Coverage Control & Plan Lookup Dataset, version 1.1, verified August 1, 2026 against a July 31, 2026 policy snapshot from the official state sources printed beneath each table.

Three date-sensitive states outside or at the edge of the census

Massachusetts: removed effective July 3, 2026

MassHealth's official notice says anti-obesity agents are no longer covered when used for obesity or overweight for dates of service beginning July 3, 2026. The exclusion does not erase separately covered non-obesity indications merely because the same product or molecule also has a weight-management indication.

Massachusetts is excluded from the 11-state total. Its removal is also evidence for the control-layer finding: a state policy changed the benefit across the program rather than managed-care plans independently rewriting their formularies.

Source: MassHealth Pharmacy Facts 278, June 25, 2026.

Utah: not an active managed-care obesity pathway on July 31

Utah's published fee-for-service prior-authorization form asks whether the member had an active weight-loss authorization between July 1, 2025 and June 30, 2026 and states that weight-management coverage was a legislative pilot that might not continue past June 30, 2026. The Utah Medicaid prior-authorization directory identifies the form as fee-for-service, and the state's 2025 pharmacy training described the obesity coverage as available to fee-for-service members only.

That produces two independent reasons not to count Utah's four ACOs in this managed-care census:

Utah's Hybrid Unified PDL and non-obesity GLP-1 pathways remain separate questions. The exclusion here is narrow: Utah is not counted as an active managed-care adult-obesity pathway on July 31.

Utah's 2026 HCR 8 does not extend Medicaid coverage. It directs the Public Employees' Benefit and Insurance Program, or PEHP, to establish an obesity pilot for public employees.

Source: Utah Medicaid fee-for-service prior-authorization directory; Utah GLP-1 Medications for Weight-related Comorbidities form; Utah 2025 statewide provider-training pharmacy slides; Utah 2026 passed-legislation summary; Utah managed-care plans.

Indiana: announced, not yet operative

Indiana announced on July 30, 2026 that its Medicaid program would move toward GLP-1 coverage for eligible beneficiaries through a forthcoming agreement. The announcement says implementation details, including eligibility criteria and timing, will be announced after the agreement is finalized. No operative date means no row in a July 31 effective-policy census.

Source: Indiana state announcement, July 30, 2026.

The plans pay. The states decide.

The clearest spending evidence comes from four states that withdrew adult-obesity coverage. Milliman published gross expenditures for Wegovy, Zepbound, and Saxenda from CMS State Drug Utilization Data, split between fee-for-service and managed care. We recomputed the managed-care shares from the published dollar figures.

Source: Shares computed by The RX Index Research from Milliman, “The evolving landscape of anti-obesity medication coverage in Medicaid,” March 19, 2026, Figure 2. The underlying period is 2023 Q1 through 2025 Q2, and the source data are CMS State Drug Utilization Data.

California is the structural outlier because its pharmacy benefit runs through the state-administered Medi-Cal Rx system. Outside California, 99.6% of the published spending in the other three withdrawal states flowed through managed care. Yet the withdrawals occurred through state policy, not through dozens of unrelated plan decisions.

The managed-care plan can be the payer without being the policy author. Those are different roles.

Two limits stay attached to the table. The figures are gross and do not subtract manufacturer rebates. State Drug Utilization Data also do not identify the indication attached to each prescription, so the totals include all approved uses of the named products, not obesity alone.

Does Medicaid coverage differ for Wegovy, Zepbound, Ozempic, and Mounjaro?

Yes. Treating the products as one interchangeable "GLP-1 coverage" category creates wrong answers. Medicaid coverage attaches to the product and medically accepted indication, while federal law permits states to exclude drugs when used for weight loss.

Ozempic and Wegovy contain semaglutide. Mounjaro and Zepbound contain tirzepatide. The shared ingredient does not make the approved uses or coverage pathways identical.

Source: FDA Ozempic label; FDA Mounjaro label; FDA Wegovy label; FDA Zepbound approval for obstructive sleep apnea; FDA Saxenda label.

The practical rule is simple: a statement that a state "doesn't cover Wegovy" is incomplete unless it names the indication. A state can exclude use for chronic weight management while maintaining a separate route for cardiovascular risk reduction or MASH. Zepbound can likewise have a separate obstructive-sleep-apnea route.

The federal coverage rule in plain English

For manufacturers participating in the Medicaid Drug Rebate Program, states generally cover covered outpatient drugs for medically accepted indications, subject to lawful utilization management and statutory exclusions. Federal law expressly permits states to exclude drugs when used for anorexia, weight loss, or weight gain. CMS has separately instructed states that a drug excluded for weight loss may still need coverage for another medically accepted indication.

Source: 42 U.S.C. § 1396r-8; CMS all-state Medicaid Drug Rebate Program presentation, May 7, 2024.

Children are a separate coverage question

Medicaid's Early and Periodic Screening, Diagnostic and Treatment benefit requires states to furnish medically necessary services within the federal Medicaid benefit categories for eligible members under 21 when needed to correct or ameliorate a condition. That is a distinct, case-specific pathway. It should not be collapsed into an adult-obesity column, and it is not represented by this dataset's adult plan rows.

Source: CMS, Early and Periodic Screening, Diagnostic and Treatment.

What do "preferred," "covered," and "prior authorization" mean?

Preferred is not the same word as approved. The terms describe different layers of the benefit.

The cleanest summary is: the list tells you what is available for consideration; the authorization criteria tell you what the request must prove.

Why does the same GLP-1 get different Medicaid answers?

At least nine variables can sit between a prescription and a paid claim:

The plan name is one variable. In 59 of the 62 rows, it is not the variable that writes the base list.

What does the CMS BALANCE model change?

BALANCE — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — is a voluntary CMS Innovation Center model for obesity treatment. For Medicaid, CMS describes manufacturer pricing arrangements implemented through state supplemental rebate agreements, standardized coverage conditions, and state participation rather than a separate plan-by-plan enrollment decision.

As of July 31, 2026:

That last point is why Indiana remains outside this snapshot. The state announced its direction on July 30 but said timing and eligibility details would follow.

The separate Medicare GLP-1 Bridge began July 1, 2026 and is scheduled through December 31, 2027. It is not a Medicaid managed-care benefit and is not counted in this dataset.

Source: CMS BALANCE model; CMS BALANCE state Medicaid request for applications; CMS Medicare GLP-1 Bridge.

How often this changes — and how the dataset is maintained

Preferred drug lists, prior-authorization criteria, plan rosters, state budgets, FDA labels, and federal model implementation do not move on the same schedule. This page is versioned so a reference can point to a defined state of the record.

Source: The RX Index Research, dataset refresh plan, version 1.1.

Two dates are deliberately kept separate. Policy effective is when the official rule applies. Last verified is when the source was rechecked. Editing a sentence does not advance the verification date.

Limitations

We would rather you know these than discover them.

Frequently asked questions

How to cite this page

The RX Index Editorial Team. "Medicaid Managed Care GLP-1 Coverage by Plan: 2026 Data."
The RX Index Research. Last verified August 1, 2026; data snapshot July 31, 2026.
https://therxindex.com/research/medicaid-managed-care-glp1-coverage-by-plan/

The RX Index Research. Medicaid GLP-1 Coverage Control & Plan Lookup Dataset,
version 1.1, data snapshot July 31, 2026.

Primary sources

Related research

Changelog

The RX Index Research is an independent research and reference resource on prescription-drug access and coverage. This page contains no sponsored content, and no commercial relationship influenced the findings. Official state Medicaid plan rosters, managed-care contracts and manuals, preferred drug lists, pharmacy-administrator documents, prior-authorization forms, dated policy notices, CMS materials, FDA labels, and national baseline analyses were assembled into one plan-level control dataset. Conclusions that could not be tied to a current operative source were excluded or stated as unresolved rather than inferred.